ATMP Symposium for Knowledge Exchange, Innovation, and Future Collaborations

Blog post by Carin Dahlberg, Scientific coordinator NextGenNK

On January 22, 2025, NextGenNK and CCRM Nordic hosted a mini-symposium at Karolinska Institutet, Campus Flemingsberg, with a focus on Advanced Therapy Medicinal Products (ATMP). The event aimed to foster networking within the ATMP field and provide insights into both academic and commercial advancements in Stockholm and Sweden.

NextGenNK and CCRM Nordic co-organized the mini-symposium to strengthen the development of ATMP by combining academic research with industrial expertise. During a half-day event, 14 presentations were delivered by representatives from academia, hospitals, and industry. Together, we aim to create a platform that facilitates innovation, production, and increased adoption of advanced therapies.

The event’s goal was to promote further collaboration and networking among researchers, clinicians, and industry partners, thereby supporting ongoing projects, contributing to the development of new initiatives, and increasing visibility for the ATMP field in Sweden. By bringing together experts and stakeholders, we strived to create a dynamic environment for knowledge sharing and future partnerships.

The mini-symposium was highly successful, with over 150 participants from more than 60 universities and companies. Attendees appreciated the opportunity to network and learn about the latest advancements in ATMP. The positive feedback highlights a strong interest in continued collaboration and development within this exciting field.

ATMP represents a rapidly growing sector in medicine, focusing on developing advanced therapies such as cell and gene therapies to treat previously incurable diseases. Progress in this area points toward more personalized treatments and innovative therapies that have the potential to revolutionize healthcare.

 Read more about the event here

Bactiguard

“Previously, we had offices in central Stockholm. When we needed more space to establish an integrated facility for all our activities, including production, Flemingsberg was the natural choice. The main reason for this was proximity to Karolinska University Hospital, Karolinska Institutet, Swedish Red Cross University College, and other key partners for us. Our technology also has links with the 1912 Nobel Prize, (read more on our website), so what could be more appropriate for our new address than Alfred Nobel Allé,”

Inhalation Sciences Sweden

“In Flemingsberg, we have access to the advanced labs that we need, and it offers the right facilities we need to expand,” says Manoush Masarrat, CEO of Inhalation Sciences.

Mando Group

“We conducted our research and development in collaboration with KI and Karolinska University Hospital here in Flemingsberg – work that paved the way for our insights into what causes obesity and ultimately its treatment. The positive environment at Campus Flemingsberg encourages original thinking and collaboration and has created a stimulating environment that has been decisive for us,” says Cecilia Bergh.

Go to Top